Jazz Pharmaceuticals (JAZZ) announced that Bruce Cozadd, Co-Founder, Chairperson and CEO, has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the company’s next leader, expected by the end of 2025. The Board will commence a formal search process to identify a new CEO, which is anticipated to conclude within 12 months. Cozadd will retire as CEO once a successor has been appointed and will continue serving as Chairperson of the Board of Directors, providing ongoing leadership and strategic guidance to the company. Jazz remains on track to meet its full year 2024 total revenue guidance of between $4B-$4.1B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- ALX Oncology to host virtual event to discuss Phase 1b/2 evorpacept data
- Jazz Pharmaceuticals upgraded to Overweight from Equal Weight at Morgan Stanley
- Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch
- ALX Oncology announces results from Phase 1b/2 trial
- Jazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines
Questions or Comments about the article? Write to editor@tipranks.com